loading page

Rosuvastatin and fenofibrate combination in the treatment of mixed hyperlipidemia: A narrative review
  • +2
  • Kaushik Biswas,
  • Ajoy Tiwari,
  • Prachi Jadhav,
  • Amit Goel,
  • G V Chanukya
Kaushik Biswas
Jai Clinic and Diabetes Care Centre

Corresponding Author:[email protected]

Author Profile
Ajoy Tiwari
Jai CLinic
Author Profile
Prachi Jadhav
CPR Hospital
Author Profile
Amit Goel
AG Centre for Diabetes and Thyroid and Endocrine
Author Profile
G V Chanukya
Dr Chanukya's Endocrine & Diabetes Centre
Author Profile


Introduction: Patients with mixed dyslipidemia are presented with high levels of low-density lipid cholesterol (LDL-C), triglycerides (TG), and reduced high-density lipid cholesterol (HDL-C). Though useful in lowering LDL-C, therapy with rosuvastatin is insufficient in optimizing the overall lipid profile, thus putting the patient at risk of residual cardiovascular risk. A combination of statin with other lipid-modifying agents has been used with more efficient lipid control and cardiovascular risk prevention. Of these, fenofibric acid is the most frequently used, along with rosuvastatin. Methods: Authors conducted a literature search of published literature to assess the use of rosuvastatin and fenofibrate combination in the management of mixed hyperlipidaemia. Results and discussion: The authors selected a total of 47 articles to be included in the review. Due to the small number of articles and heterogeneity on the combination of rosuvastatin and fenofibrate combination in mixed hyperlipidemia, the findings herein are presented using narrative summaries. Based on the thorough assessment of the selected literature, the essential themes that emerged from the review include safety and efficacy of rosuvastatin and fenofibrate combination, place of therapy of rosuvastatin, and fenofibrate combination, and potential cardiovascular risk reduction with rosuvastatin and fenofibrate combination. Conclusion: Based on the review, the authors suggested that the combination therapy with fenofibric acid was beneficial, well-tolerated with a similar safety profile compared with statin monotherapy. The combination therapy of moderate dose rosuvastatin and fenofibric acid led to a reduction of cardiovascular risk factors via several pathways.